Skip to main content

Peer Review reports

From: Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Original Submission
20 Jun 2023 Submitted Original manuscript
16 Sep 2023 Reviewed Reviewer Report
25 Sep 2023 Reviewed Reviewer Report
18 Oct 2023 Author responded Author comments - Yong Won Choi
22 Oct 2023 Author responded Author comments - Yong Won Choi
Resubmission - Version 2
18 Oct 2023 Submitted Manuscript version 2
30 Nov 2023 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
21 Dec 2023 Editorially accepted
12 Jan 2024 Article published 10.1186/s12885-023-11782-6

You can find further information about peer review here.

Back to article page